secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001213900-24-111528
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx CEO William Febbo to step down Dec 31; President Stephen Silvestro named interim CEO
--------------------------------------------------------------------------------

- CEO William Febbo departs effective Dec 31, 2024; will provide advisory services through March 2025.
- Board appoints President Stephen Silvestro as interim CEO; search for permanent CEO initiated.
- Company reaffirms FY2024 guidance; expects revenue and adjusted EBITDA at higher end of range.
- Febbo had been CEO for nearly nine years; board expresses gratitude and confidence in team.
- Silvestro joined OptimizeRx in 2019, became President in October 2023; previously Chief Commercial Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024111528/0001213900-24-111528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024111528/ea0225680-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-111528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer